Fran Lowry | Authors

Next gen EGFR targeting drug promising in NSCLC

December 29, 2010

Finding an effective treatment for all the complex iterations of cancer is akin to chasing an outlaw through a treacherous mountain range, in the estimation of Louis M. Weiner, MD, director of the Georgetown Lombardi Comprehensive Cancer Center in Washington, DC.

Trastuzumab-DM1 delivers encouraging results in HER2+ breast cancer

December 29, 2010

Impressive results from an ongoing study of an anti-HER2 antibody-drug conjugate in HER2-positive metastatic breast cancer has already fast-tracked a phase III trial.Trastuzumab-DM1 (T-DM1) has demonstrated comparable results to standard treatment but with much less grade 3-4 toxicity in phase II trial results.

Novel HDAC inhibitor offers hope in heavily pretreated HL patients

December 09, 2010

Phase II study results are encouraging because this patient population generally sees a median of five prior lines of therapy including transplants, explained Jeffrey M. Besterman, MD, PhD, executive vice president and chief scientific officer for MethylGene, the developer of mocetinostat (MGCD0103).

Nilotinib Exerts Positive Effect in Early Chronic Phase Ph+ CML

December 07, 2010

At a median follow-up of 36 months, multiple survival rates were nearly perfect at 99%. The leader of the Italian study called the low number of treatment failures reassuring news as to the durability of nilotinib response at three years post-therapy

Dasatinib Moves Ahead of Imatinib as Front-line Therapy for Newly Diagnosed CML in Chronic Phase

December 07, 2010

The likelihood of patients achieving complete cytogenetic response at any time was 1.5 times higher with dasatinib (Sprycel) than with imatinib (Gleevec), according to an investigator with the DASISION trial.

Dose-escalated BEACOPP should become new standard of care for early unfavorable Hodgkin’s lymphoma

December 06, 2010

The intensified regimen of BEACOPP plus standard therapy ABVD plus radiotherapy bested four cycles of ABVD alone, leading to a significant improvement in tumor control. Final results from the German Hodgkin Study Group trial saw a 7% improvement in terms of freedom from treatment failure between the standard and new treatment arms.

Nilotinib Continues to Surpass Imatinib in Newly Diagnosed CML

December 06, 2010

The 24-month follow-up data from the ENESTnd trial showed that patients treated with nilotinib (Tasigna) had significantly better response rates and significantly lower rates of progression to accelerated phase or blast crisis when on treatment

Imatinib readies patients with Philadelphia-positive ALL for allogeneic stem cell transplant

December 06, 2010

Patients in a major UK/US trial who received imatinib had improved overall survival, event-free survival, and relapse-free survival at three years of follow-up compared with patients who did not receive any imatinib.

Bevacizumab Offers New Hope to Ovarian Cancer Patients

December 04, 2010

Early results from the ICON7 trial suggest that adding bevacizumab (Avastin) to standard chemotherapy in women with newly diagnosed ovarian cancer reduces the risk of disease progression during the first year of treatment.

From the ONI archives: Hereditary breast cancer patients benefit from multidisciplinary approach

December 03, 2010

For women with hereditary breast cancer, deciding on the best treatment option can be challenging. Three specialists, including medical oncologist Susan M. Domchek, MD, discuss the different approaches to managing breast cancer patients with a family history of BRCA mutations. Dr. Domchek will give a talk at SABCS 2010 on the management of women with a significant predisposition to breast cancer.